All Title Author
Keywords Abstract


Sulfamethoxazole-Trimethoprim-Induced Rhabdomyolysis in an Immunocompetent Patient: A Case Report

DOI: 10.4236/crcm.2017.612037, PP. 311-316

Keywords: Rhabdomyolysis, Sulfamethoxazole-Trimethoprim, Immunocompetent

Full-Text   Cite this paper   Add to My Lib

Abstract:

Sulfamethoxazole-trimethoprim (TMP-SMX)-induced rhabdomyolysis is a rare complication of a commonly used antibiotic. This is a case report of a 43-year old immunocompetent African American woman with a history of depression and chronic alcohol consumption who presented to the emergency department (ED) with worsening bilateral leg pain. Before presentation, the patient was prescribed a twice daily dose of TMP-SMX for a urinary tract infection. The patient reported the development of intensifying leg pain after taking five doses of TMP-SMX. On presentation to the ED she was hemodynamically stable, afebrile, and leg pain intensity 10 out of 10. The patient admitted to daily alcohol consumption and taking vortioxetine 10 mg per day for treatment of depression. Initial labs drawn in the ED showed an elevated creatine kinase (CK) of 26,231 U/L and a normal serum creatinine (SCr) of 1 mg/dL. Through patient history and laboratory tests, common causes of rhabdomyolysis were ruled out. Treatment was initiated with IV fluids plus thiamine and folic acid supplementation, TMP-SMX was discontinued, and vortioxetine 10 mg per day was continued until hospital day five. The patient began to show improvement in lower extremity pain and tenderness and was discharged on hospital day eight with minimal residual leg pain and a CK of 2809 U/L. This case report presents only the third incidence of an immunocompetent patient developing TMP-SMX-induced rhabdomyolysis. This case highlights an opportunity for a pharmacist’s intervention and the need for future research to determine risk factors of TMP-SMX-induced rhabdomyolysis in immunocompetent patients.

References

[1]  Zutt, R., van der Kooi, A.J., Linthorst, G.E., Wanders, R.J.A. and de Visser, M. (2014) Rhabdomyolysis: Review of the Literature. Neuromuscular Disorders (NMD), 24, 651-659.
https://doi.org/10.1016/j.nmd.2014.05.005
[2]  Allison, R.C. and Lawrence Bedsole, D. (2003) The Other Medical Causes of Rhabdomyolysis. The American Journal of the Medical Sciences, 326, 79-88.
https://doi.org/10.1097/00000441-200308000-00005
[3]  Vale, A. (2016) Rhabdomyolysis. Medicine (Baltimore), 44, 93-94.
https://doi.org/10.1016/j.mpmed.2015.11.002
[4]  Coco, T.J. and Klasner, A.E. (2004) Drug-Induced Rhabdomyolysis. Current Opinion in Pediatrics, 16, 206-210.
https://doi.org/10.1097/00008480-200404000-00017
[5]  Antons, K.A., Williams, C.D., Baker, S.K. and Phillips, P.S. (2006) Clinical Perspectives of Statin-Induced Rhabdomyolysis. The American Journal of Medicine, 119, 400-409.
https://doi.org/10.1016/j.amjmed.2006.02.007
[6]  Members, W.C., Pasternak, R.C., Smith, S.C., et al. (2002) ACC/AHA/NHLBI Clinical Advisory on the Use and Safety of Statins. Stroke, 33, 2337-2341.
https://doi.org/10.1161/01.str.0000034125.94759.41
[7]  Melli, G., Chaudhry, V. and Cornblath, D.R. (2005) Rhabdomyolysis: An Evaluation of 475 Hospitalized Patients. Medicine (Baltimore), 84, 377-385.
https://doi.org/10.1097/01.md.0000188565.48918.41
[8]  Gabow, P.A., Kaehny, W.D. and Kelleher, S.P. (1982) The Spectrum of Rhabdomyolysis. Medicine (Baltimore), 61, 141-152.
https://doi.org/10.1097/00005792-198205000-00002
[9]  Will You Have Rhabdomyolysis with Bactrim—From FDA Reports—eHealthMe.
https://www.ehealthme.com/ds/bactrim/rhabdomyolysis/
[10]  Walker, S., Norwood, J., Thornton, C. and Schaberg, D. (2006) Trimethoprim-Sul-famethoxazole Associated Rhabdomyolysis in a Patient with AIDS: Case Report and Review of the Literature. The American Journal of the Medical Sciences, 331, 339-341.
https://doi.org/10.1097/00000441-200606000-00011
[11]  Augustyn, A., Lisa Alattar, M. and Naina, H. (2015) Rhabdomyolysis Due to Trimethoprim-Sulfamethoxazole Administration Following a Hematopoietic Stem Cell Transplant. Case Reports in Oncological Medicine.
[12]  Huang, J.C., Gold, S., McManus, K.A. and Wispelwey, B. (2013) Case Report: Rhabdomyolysis in the Setting of Acute Human Immunodeficiency Virus Infection. Case Reports in Clinical Medicine, 2, 198.
https://doi.org/10.4236/crcm.2013.23054
[13]  Kiel, P.J., Dickmeyer, N. and Schwartz, J.E. (2010) Trimethoprim-Sulfamethoxa-zole-Induced Rhabdomyolysis in an Allogeneic Stem Cell Transplant Patient. Transplant Infectious Disease, 12, 451-454.
https://doi.org/10.1111/j.1399-3062.2010.00524.x
[14]  Ainapurapu, B. and Kanakadandi, U.B. (2014) Trimethoprim-Sulfamethoxazole In-duced Rhabdomyolysis. American Journal of Therapeutics, 21, e78-e79.
https://doi.org/10.1097/MJT.0b013e31824567fe
[15]  Petrov, M., Yatsynovich, Y. and Lionte, C. (2015) An Unusual Cause of Rhabdomyolysis in Emergency Setting: Challenges of Diagnosis. American Journal of Emergency Medicine, 33, 123.e1-123.e3.
https://doi.org/10.1016/j.ajem.2014.05.041
[16]  Zimmerman, J.L. and Shen, M.C. (2013) Rhabdomyolysis. Chest, 144, 1058-1065.
https://doi.org/10.1378/chest.12-2016
[17]  Huang, S.-S., Yang, H.-Y., Lin, Y.-C. and Chan, C.-H. (2012) Low-Dose Venlafaxine-Induced Severe Rhabdomyolysis: A Case Report. General Hospital Psychiatry, 34, 436.e5-7.
https://doi.org/10.1016/j.genhosppsych.2012.01.016

Full-Text

comments powered by Disqus